Journal
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 33, Issue 8, Pages 1030-1033Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0269881119849815
Keywords
Behavioral and psychological symptoms of dementia (BPSD); N-methyl-D-aspartate; D-amino acid oxidase (DAAO) inhibitor; sodium benzoate
Funding
- National Science Council, Taiwan [NSC 101-2325-B-039-009, NSC 102-2325-B-039-009, MOST 103-2325-B-039-004, MOST 105-2325-B-039-005, MOST 107-2321-B-039-003]
- Ministry of Science and Technology, Taiwan [NSC 101-2325-B-039-009, NSC 102-2325-B-039-009, MOST 103-2325-B-039-004, MOST 105-2325-B-039-005, MOST 107-2321-B-039-003]
- China Medical University Hospital, Taiwan [DMR-107-089]
- Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW 107-TDU-B-212-123004]
Ask authors/readers for more resources
Objective: Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer's disease (AD) after 24-week treatment. This study examined benzoate treatment for behavioral and psychological symptoms of dementia (BPSD). Methods: In a double-blind, 6-week trial, 97 patients with BPSD were randomized to receive placebo or benzoate (mean dose: 622.0 mg/day). The primary outcomes were ADAS-cog and BEHAVE-AD. Results: Two treatments showed similar safety and primary and secondary outcomes. Conclusions: Compared to antecedent 24-week, higher-dose treatment for early-phase AD, benzoate appeared ineffective in this 6-week trial. Longer-duration, higher-dose trials are warranted to clarify its efficacy for BPSD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
